Aurobindo Pharma

EBITDA margin expands from 20.4% in Q1 FY26 to 21.0% in Q1 FY27, confirming improved pricing power and operational efficiency.

Cash and investments fall from ₹10,676 Cr in Q4 FY26 to ₹8,790 Cr in Q1 FY27, signaling a notable liquidity drawdown.

Formulation revenue grows from ₹6,953 Cr in Q1 FY26 to ₹8,101 Cr in Q1 FY27, driven by strong demand across Europe and growth markets.

Foreign exchange loans climb from ₹5,299 Cr in Q1 FY26 to ₹7,472 Cr in Q1 FY27, increasing currency risk exposure amid rupee depreciation.

ANDA filings increase from 865 in Q1 FY26 to 896 in Q1 FY27, reflecting a robust pipeline for future US market approvals.

US revenue drops from $420 Mn in Q3 FY26 to $387 Mn in Q4 FY26, indicating temporary sales pressure in the key American market.

Net debt improves from -₹1,204 Cr in Q1 FY26 to -₹397 Cr in Q1 FY27, demonstrating successful deleveraging and lower interest burden.

Working capital loans rise from $185 Mn in Q1 FY26 to $800 Mn in Q1 FY27, reflecting higher operational funding requirements.

Beta-lactam API revenue rises from ₹633 Cr in Q1 FY26 to ₹800 Cr in Q1 FY27, highlighting sustained demand in the core API segment.

Addressable market size contracts from $197.2 Mn in Q3 FY26 to $182.3 Mn in Q1 FY27, pointing to a shrinking opportunity space in key formulation segments.